Extended release formulations

Details for Australian Patent Application No. 2006239838 (hide)

Owner Teva Pharmaceuticals USA, Inc.

Inventors Chungi, Shubha

Agent Shelston IP

Pub. Number AU-A-2006239838

PCT Pub. Number WO2006/116247

Priority 60/674,444 25.04.05 US

Filing date 25 April 2006

Wipo publication date 2 November 2006

International Classifications

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 31/192 (2006.01)

A61K 31/405 (2006.01)

A61K 31/4402 (2006.01) - only substituted in position 2, e.g. pheniramine, bisacodyl

A61K 31/535 (2006.01) - having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

Event Publications

29 November 2007 PCT application entered the National Phase

  PCT publication WO2006/116247 Priority application(s): WO2006/116247

25 March 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006239843-Methods for non-thermal application of gas plasma to living tissue

2006239825-Drive systems and devices incorporating drive systems